BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway

BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway

Background: Osteosarcoma, a tumor that originates from bone cells, has a poor prognosis and a high degree of malignancy. Anlotinib, a small-molecule multi-target tyrosine kinase inhibitor (TKI), is the first-line drug in treating osteosarcoma, especially in late-stage osteosarcoma. However, patients...

Full description

Bibliographic Details
Main Authors: Qingtao Meng, Jian Han, Peng Wang, Chenxu Jia, Mingyang Guan, Bolun Zhang, Wenzhi Zhao
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Journal of Bone Oncology
Subjects:
Osteosarcoma
Anlotinib
VEGFR
CDK2
Synergy effect
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137424000745

Internet

http://www.sciencedirect.com/science/article/pii/S2212137424000745

Similar Items